The increased reimbursement makes out product more competitive as doctors receive a larger rebate so increases the likeliness of surgeons recommending/using our technology and thus will should lead to a significant increase in sales
Ann: Full Year Financial Results, page-44
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.52M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 19.5¢ | 19.0¢ | $4.299K | 22.16K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 68058 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 43366 | 2 |
View Market Depth
| Last trade - 10.38am 03/10/2024 (20 minute delay) ? |
| EYE (ASX) Chart |